Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial
Clinical Trial
Published on
Journal: Enfermedades infecciosas y microbiologia clinica ( [Category] COVID19(2023년), SARS, 임상,
Journal: Enfermedades infecciosas y microbiologia clinica ( [Category] COVID19(2023년), SARS, 임상,
[키워드] 95%CI
Admission
asked
benefit
both groups
clinical symptom
Comorbidities
contraindication
Control
control group
COVID-19
decrease
diarrhea
died
Disease progression
Efficacy and safety
English
female
FIVE
Follow-up
HCQ
Health
Health care worker
Healthcare professional
healthcare worker
Healthcare workers
Hidroxicloroquina
Hospitalization
Hydroxychloroquine
in both groups
in viral
Infección por SARS-CoV-2
initial
intensive care unit
Loading dose
media
median age
Mild
mild SARS-CoV-2 infection
Negative conversion
no significant difference
non-randomized
non-randomized trial
outcome
outpatients
Pacientes externos
Patient
PCR
Pneumonia
primer
Probability
professional
Prospective
prospectivo
reduction in
required
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 viral load
Side effect
significant difference
Spanish
Symptom
Trabajadores sanitarios.
Treatment
treatment group
Two patient
viral dynamics
were given
[DOI] 10.1016/j.eimce.2020.10.015 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1016/j.eimce.2020.10.015 PMC 바로가기 [Article Type] Clinical Trial